Research & development

Infant Bacterial Therapeutics' most advanced clinical program is the IBP-9414 project developing a preventive treatment against necrotizing enterocolitis (NEC).
Read more

What we do

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants.
Read More